Skip to main content
SpringerLink
Log in

Fungal Infections Post Stem Cell Transplant

  • Chapter
  • First Online:
Basics of Hematopoietic Stem Cell Transplant

  • 413 Accesses

Abstract

Fungus is one of the most common environmental pathogens and one of the most prevalent infective organisms among immunocompromised patients. It can be single-celled or multinucleate and its cell membrane has a unique sterol (ergosterol) which replaces cholesterol found in human cell membranes. Candida, aspergillus and mucor are the most common fungal infections seen in patients with hematological malignancies and those undergoing stem cell transplant (SCT). A hemato-oncologist should keep a high index of suspicion in any patient at risk for fungal infections as these infections are highly fatal if not timely treated. Antifungal agents selectively eliminate fungal pathogens from a host.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011;3:175–91.

    PubMed  PubMed Central  Google Scholar 

  2. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8):1068–75.

    PubMed  Google Scholar 

  3. Nucci M, Anaissie E. How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. Blood. 2014;124(26):3858–69.

    Article  CAS  PubMed  Google Scholar 

  4. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236–301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Agrawal S, Jones B, Barnes R, Kibbler C, Millen M, Ashcroft M, et al. A practical critique of antifungal treatment guidelines for haemato-oncologists. Crit Rev Microbiol. 2012;38(3):203–16.

    Article  CAS  PubMed  Google Scholar 

  6. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol Off J Am Soc Clin Oncol. 1997;15(1):139–47.

    Article  CAS  Google Scholar 

  7. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):427–31.

    Article  PubMed  Google Scholar 

  8. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367–76.

    Article  PubMed  Google Scholar 

  9. Bow EJ. Of yeasts and hyphae: a hematologist’s approach to antifungal therapy. Hematology. 2006;1:361–7.

    Article  Google Scholar 

  10. Thaler M, Pastakia B, Shawker TH, O’Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med. 1988;108(1):88–100.

    Article  CAS  PubMed  Google Scholar 

  11. Cole GT, Lynn KT, Seshan KR. Evaluation of a murine model of hepatic candidiasis. J Clin Microbiol. 1990;28(8):1828–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. van Burik JH, Leisenring W, Myerson D, Hackman RC, Shulman HM, Sale GE, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore). 1998;77(4):246–54.

    Article  PubMed  Google Scholar 

  13. Garcia-Vidal C, Viasus D, Carratalà J. Pathogenesis of invasive fungal infections. Curr Opin Infect Dis. 2013;26(3):270–6.

    Article  CAS  PubMed  Google Scholar 

  14. Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of aspergillus spp.: implications for pathogenesis. Microbiology. 1994;140(Pt 9):2475–9.

    Article  CAS  PubMed  Google Scholar 

  15. Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5–26.

    Article  CAS  PubMed  Google Scholar 

  16. Jha AK, Bansal D, Chakrabarti A, Shivaprakash MR, Trehan A, Marwaha RK. Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies. Mycoses. 2013;56(4):442–8.

    Article  CAS  PubMed  Google Scholar 

  17. Fleming S, Yannakou CK, Haeusler GM, Clark J, Grigg A, Heath CH, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44(12b):1283–97.

    Article  CAS  PubMed  Google Scholar 

  18. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–52.

    Article  CAS  PubMed  Google Scholar 

  19. Marr KA, Bow E, Chiller T, Maschmeyer G, Ribaud P, Segal B, et al. Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009;44(8):483–7.

    Article  CAS  PubMed  Google Scholar 

  20. Legrand F, Lecuit M, Dupont B, Bellaton E, Huerre M, Rohrlich PS, et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis. 2008;46(5):696–702.

    Article  CAS  PubMed  Google Scholar 

  21. Abdul Salam ZH, Karlin RB, Ling ML, Yang KS. The impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a large acute tertiary-care hospital. Am J Infect Control. 2010;38(4):e1–7.

    Article  PubMed  Google Scholar 

  22. Bouza E, Almirante B, Rodríguez JG, Garnacho-Montero J, Salavert M, Muñoz P, et al. Biomarkers of fungal infection: expert opinion on the current situation. Rev Esp Quimioter. 2020;33(1):1–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Latgé JP, Kobayashi H, Debeaupuis JP, Diaquin M, Sarfati J, Wieruszeski JM, et al. Chemical and immunological characterization of the extracellular galactomannan of aspergillus fumigatus. Infect Immun. 1994;62(12):5424–33.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, et al. Pathogenesis of aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis. 2007;195(3):455–66.

    Article  CAS  PubMed  Google Scholar 

  25. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42(10):1417–727.

    Article  CAS  PubMed  Google Scholar 

  26. Patterson TF, Thompson GR III, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–60.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Miceli MH, Grazziutti ML, Woods G, Zhao W, Kocoglu MH, Barlogie B, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis. 2008;46(9):1412–22.

    Article  PubMed  Google Scholar 

  28. Nucci M, Nouér SA, Cappone D, Anaissie E. Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome. Haematologica. 2013;98(11):1657–60.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Sharma SK, Kumar S, Singh AK, Seth T, Mishra P, Mahapatra M, et al. Feasibility and outcome of CT-guided lung biopsy in patients with hematological diseases and suspected fungal pneumonia. J Infect Dev Ctries. 2013;7(10):748–52.

    Article  PubMed  Google Scholar 

  30. Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev. 2011;24(2):247–80.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(1):253–9.

    Article  CAS  Google Scholar 

  32. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15(1):139–47.

    Article  CAS  PubMed  Google Scholar 

  33. Austin JH, Müller NL, Friedman PJ, Hansell DM, Naidich DP, Remy-Jardin M, et al. Glossary of terms for CT of the lungs: recommendations of the nomenclature committee of the fleischner society. Radiology. 1996;200(2):327–31.

    Article  CAS  PubMed  Google Scholar 

  34. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis. 2011;52(9):1144–55.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Gintjee TJ, Donnelley MA, Thompson GR. Aspiring antifungals: review of current antifungal pipeline developments. J Fungi (Basel). 2020;6(1):28.

    Article  CAS  PubMed  Google Scholar 

  36. Arikan S, Rex JH. Lipid-based antifungal agents: current status. Curr Pharm Des. 2001;7(5):393–415.

    Article  CAS  PubMed  Google Scholar 

  37. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988;32(1):1–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Bowman JC, Hicks PS, Kurtz MB, Rosen H, Schmatz DM, Liberator PA, et al. The antifungal echinocandin caspofungin acetate kills growing cells of aspergillus fumigatus in vitro. Antimicrob Agents Chemother. 2002;46(9):3001–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Waldorf AR, Polak A. Mechanisms of action of 5-fluorocytosine. Antimicrob Agents Chemother. 1983;23(1):79–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15.

    Article  CAS  PubMed  Google Scholar 

  41. Ethier MC, Science M, Beyene J, Briel M, Lehrnbecher T, Sung L. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials. Br J Cancer. 2012;106(10):1626–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012;56(6):3032–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Cheng JT, Witty RT, Robinson RR, Yarger WE. Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. Kidney Int. 1982;22(6):626–33.

    Article  CAS  PubMed  Google Scholar 

  44. Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin N Am. 2016;30(1):51–83.

    Article  Google Scholar 

  45. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–50.

    Article  PubMed  Google Scholar 

  46. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 2002;49(Suppl 1):7–10.

    Article  CAS  PubMed  Google Scholar 

  47. Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011;86(8):805–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563–71.

    Article  CAS  PubMed  Google Scholar 

  49. Johnson MD, Perfect JR. Use of antifungal combination therapy: agents, order, and timing. Curr Fungal Infect Rep. 2010;4(2):87–95.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Meletiadis J, Petraitis V, Petraitiene R, Lin P, Stergiopoulou T, Kelaher AM, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis. 2006;194(7):1008–18.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hemato-oncology and Bone Marrow Transplantation, Venkateshwar Hospital, New Delhi, Delhi, India

    Sanjeev Kumar Sharma

Authors
  1. Sanjeev Kumar Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sharma, S.K. (2023). Fungal Infections Post Stem Cell Transplant. In: Basics of Hematopoietic Stem Cell Transplant. Springer, Singapore. https://doi.org/10.1007/978-981-19-5802-1_44

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-5802-1_44

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-5801-4

  • Online ISBN: 978-981-19-5802-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation